Kuros BiosciencesCSBTF 71 EV-to-FCF is -245.14 as of Jun. 27, 2026. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 421 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 237529.45% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kuros Biosciences's Enterprise Value is $871.7 Mil.
Kuros Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.6 Mil. Therefore, Kuros Biosciences's EV-to-FCF for today is -245.14.
The historical rank and industry rank for Kuros Biosciences's EV-to-FCF or its related term are showing as below:
CSBTF'
s EV-to-FCF Range Over the Past 10 Years
Min: -397.2 Med: -3.43 Max: 534.83
Current: -245.14
During the past 13 years, the highest EV-to-FCF of Kuros Biosciences was 534.83. The lowest was -397.20. And the median was -3.43.
CSBTF's EV-to-FCF is ranked worse than 100% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 22.82
vs CSBTF: -245.14
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kuros Biosciences (OTCPK:CSBTF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kuros Biosciences's PE Ratio (TTM) for today is calculated as:
Kuros Biosciences's share price for today is $22.72.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.089.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kuros Biosciences EV-to-FCF Related Terms
Kuros Biosciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's EV-to-FCF falls into.
Kuros Biosciences's current Enterprise Value is $871.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a EV-to-FCF of -245.14 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #999999 out of 421 companies in the Medical Devices & Instruments industry.
Is Kuros Biosciences' EV-to-FCF too high?
Kuros Biosciences' current EV-to-FCF is -245.14. Based on the distribution chart, Kuros Biosciences ranks #999999 out of 421 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #999999 out of 421 companies for EV-to-FCF. This places Kuros Biosciences in the lower half of its industry. The industry median EV-to-FCF is 22.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.82, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current EV-to-FCF is -245.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current EV-to-FCF is -245.14. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current EV-to-FCF is -245.14 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
EV-to-FCF: -245.14
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
